Is chemotherapy working if there are no side effects?

 

Q: My father had his first chemo treatment a week ago and has not shown any of the side effects we were told to look for. Does this mean the chemo is not working?

A: The presence, or absence, of side effects is not an indication of whether chemotherapy is working. Some people experience no side effects; others have significant trouble with them. Side effects may begin gradually and worsen as treatment progresses, or start out as severe and lessen with time.

Health care providers prepare patients and families by discussing possible side effects. The actual side effects that occur (if any) depend upon the type of chemotherapy drug or drugs, the amount given, and the individual’s own physical response to the medication. Many newer drugs produce fewer or less severe side effects.

--Kathy Newman, RN, BSN

Get acquainted with the possible side effects of cancer treatment and how they can be managed.

Latest Cancer News
Test Available for Pre-surgical Evaluation of Ovarian Mass

March 11, 2010 — For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic oncologist.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Select news items provided by Reuters Health